Recurrence analysis of glioblastoma cases based on distance and dose information

•First recurrence analysis taking the actual distance of recurrences into account.•Most of the recurrences appeared within the GTV or very close to its boundary.•Relatively larger irradiated volumes didn’t show any benefit in survival.•Smaller GTV had a higher rate of distant recurrences. Radiation...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Radiotherapy and oncology 2023-06, Vol.183, p.109600-109600, Article 109600
Hauptverfasser: Langhans, Marco, Popp, Ilinca, Grosu, Anca L., Shusharina, Nadya, Binder, Harald, Baltas, Dimos, Bortfeld, Thomas
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•First recurrence analysis taking the actual distance of recurrences into account.•Most of the recurrences appeared within the GTV or very close to its boundary.•Relatively larger irradiated volumes didn’t show any benefit in survival.•Smaller GTV had a higher rate of distant recurrences. Radiation therapy for glioblastoma (GBM) typically involves large target volumes. The aim of this study was to examine the recurrence pattern of GBM following modern radiochemotherapy according to EORTC guidelines and provide dose and distance information for the choice of optimal target volume margins. In this study, the recurrences of 97 GBM patients, treated with radiochemotherapy from 2013 to 2017 at the Medical Center- University of Freiburg, Germany were analysed. Dose and distance based metrices were used to derive recurrence patterns. The majority of recurrences (75%) occurred locally within the primary tumor area. Smaller GTVs had a higher rate of distant recurrences. Larger treated volumes did not show a clinical benefit regarding progression free and overall survival. The identified recurrence pattern suggests that adjustments or reductions in target volume margins are feasible and could result in similar survival rates, potentially combined with a lower risk of side effects.
ISSN:0167-8140
1879-0887
DOI:10.1016/j.radonc.2023.109600